Humana Inc. (NYSE: HUM) one of the nation’s leading health and well-being companies and Boehringer Ingelheim Pharmaceuticals Inc. a research-based global pharmaceutical company today announced a multi-year collaboration dedicated to improving health care and reducing costs for people affected by chronic obstructive pulmonary disease (COPD) cardiovascular disease and other chronic disease states.
The partnership will leverage the strategic strengths of both organizations to promote population health initially focusing on the early identification of COPD and other chronic diseases. Humana and Boehringer Ingelheim will bring their combined health care and research expertise together with the goal of enhancing patient health while reducing overall health care costs.
“This strategic partnership will allow us to develop a better understanding of how to improve the quality of care and better serve the immediate and long term needs of our health care population” said William Fleming Pharm.D. President of Humana Pharmacy Solutions. “It is our hope that this collaboration will ultimately create solutions and produce data that will better inform the diagnosis understanding and application of therapeutic interventions used to improve the health of people affected by COPD and cardiovascular disease as well as other targeted chronic diseases.”
“We believe that the combination of Humana’s experience and Boehringer Ingelheim’s commitment to delivering more health with a focus on driving advancements in chronic conditions including COPD and cardiovascular disease will help improve the health of the populations we serve” said Jeff Huth Senior Vice President Managed Markets Boehringer Ingelheim Pharmaceuticals Inc. “Through this important collaboration we will harness the expertise of both organizations to identify and further develop ways to improve health care delivery and health outcomes for patients.”
Chronic diseases take a toll on population health. The American Lung Association reports that more than 12 million Americans are living with COPD as well as an estimated 12 million more undiagnosed cases. According to the Centers for Disease Control and Prevention half of all Americans meet at least one of the key risk factors for cardiovascular disease: high blood pressure high LDL cholesterol or smoking.
Humana Inc. headquartered in Louisville Ky. is a leading health care company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. By leveraging the strengths of its core businesses Humana believes it can better explore opportunities for existing and emerging adjacencies in health care that can further enhance wellness opportunities for the millions of people across the nation with whom the company has relationships.
More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com including copies of:
About Boehringer Ingelheim Pharmaceuticals Inc.
Boehringer Ingelheim Pharmaceuticals Inc. based in Ridgefield CT is the largest U.S. Subsidiary of Boehringer Ingelheim Corporation (Ridgefield CT) and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim Germany it operates globally with 145 affiliates and more than 44000 employees. Since it was founded in 1885 the family-owned company has been committed to researching developing manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. Our focus is primarily in the therapeutic areas of cardiovascular disease respiratory diseases diseases of the central nervous system metabolic diseases virological diseases and oncology.
As a central element of its culture Boehringer Ingelheim pledges to act in a socially responsible manner. Involvement in social projects caring for employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.Business Wire
Last updated on: 25/03/2013